ARTICLE | Company News
Orega Biotech, Innate Pharma deal
February 1, 2016 8:00 AM UTC
Orega granted Innate exclusive, worldwide rights to develop and commercialize a program of undisclosed antibodies against ectonucleoside triphosphate diphosphohydrolase 1 ( ENTPD1; CD39) that are in...